An Argument for the Use of Aminoglycosides in the Empiric Treatment of Ventilator-Associated Pneumonia

Surgical Infections

Volumn 17, Issue 3, 2016, Pages 329-333

  May, Addison K ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; LENGTH OF STAY; META ANALYSIS; MORTALITY RATE; NEPHROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; PNEUMONIA, VENTILATOR-ASSOCIATED;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

EID: 84971280246     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2015.276     Document Type: Article

References (40)

1. Boyer A, Gruson D, Bouchet S, et al. Aminoglycosides in septic shock: An overview, with specific consideration given to their nephrotoxic risk. Drug Saf 2013;36:217-230.
2. Davis BD. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev 1987;51:341-350.
3. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996;22:387-394.
4. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999;115: 462-474.
5. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilatorassociated pneumonia. Chest 1997;111:676-685.
6. Rello J, Gallego M, Mariscal D, et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156:196-200.
7. Rello J, Ulldemolins M, Lisboa T, Koulenti D, et al. Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia. Eur Respir J 2011;37:1332-1339.
8. Beardsley JR, Williamson JC, Johnson JW, et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. Chest 2006;130:787-793.
9. Bhat S, Fujitani S, Potoski BA, et al. Pseudomonas aeruginosa infections in the Intensive care unit: Can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int J Antimicrob Agents 2007;30:458-462.
10. Celis R, Torres A, Gatell JM, et al. Nosocomial pneumonia: A multivariate analysis of risk and prognosis. Chest 1988; 93:318-324.
11. Martinez JA, Cobos-Trigueros N, Soriano A, et al. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother 2010;54:3590-3596.
12. Kollef KE, Schramm GE, Wills AR, et al. Predictors of 30-day mortality and hospital costs in patients with ventilatorassociated pneumonia attributed to potentially antibioticresistant gram-negative bacteria. Chest 2008;134:281-287.
13. Tseng CC, Liu SF, Wang CC, et al. Impact of clinical severity index, infective pathogens, and initial empiric antibiotic use on hospital mortality in patients with ventilatorassociated pneumonia. Am J Infect Control 2012;40: 648-652.
14. Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: A prospective case-control study. Crit Care Med 2001;29:2303-2309.
15. Clec¢h C, Timsit JF, De LA, et al. Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: Influence of disease severity. Intensive Care Med 2004;30: 1327-1333.
16. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001;27:355-362.
17. Dupont H, Montravers P, Gauzit R, et al. Outcome of postoperative pneumonia in the Eole study. Intensive Care Med 2003;29:179-188.
18. Hanes SD, Demirkan K, Tolley E, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002;35:228-235.
19. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262-268.
20. Leroy O, Meybeck A, d¢Escrivan T, et al. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med 2003;29:2170-2173.
21. Mueller EW, Hanes SD, Croce MA, et al. Effect from multiple episodes of inadequate empiric antibiotic ther-apy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients. J Trauma 2005;58:94-101.
22. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: A pilot study. Am J Respir Crit Care Med 1998;157:371-376.
23. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003;31:676-682.
24. Vogelaers D, De BD, Foret F, et al. Patterns of antimicrobial therapy in severe nosocomial infections: Empiric choices, proportion of appropriate therapy, and adaptation rates-A multicentre, observational survey in critically ill patients. Int J Antimicrob Agents 2010;35:375-381.
25. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
26. Eggimann P, Revelly JP. Should antibiotic combinations be used to treat ventilator-associated pneumonia? Semin Respir Crit Care Med 2006;27:68-81.
27. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001;29:1109-1115.
28. Dortch MJ, Fleming SB, Kauffmann RM, et al. Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcareassociated infections. Surg Infect 2011;12:15-25.
29. Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis. Crit Care Med 2010;38:1773-1785.
30. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/ meta-regression study. Crit Care Med 2010;38:1651-1664.
31. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007;35:1888-1895.
32. Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006;(1):CD003344.
33. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4: 519-527.
34. Aarts MA, Hancock JN, Heyland D, et al. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: A systematic review and meta-analysis of randomized trials. Crit Care Med 2008;36:108-117.
35. Salva S, Borgatta B, Rello J. Pneumonia in immunocompetent patients: Combination antibiotic therapy. Minerva Anestesiol 2014;80:495-503.
36. Hilf M, Yu VL, Sharp J, Zuravleff JJ, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-546.
37. Pereira JM, Paiva JA, Rello J. Severe sepsis in communityacquired pneumonia-Early recognition and treatment. Eur J Intern Med 2012;23:412-419.
38. Mueller EW, Boucher BA. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. Surg Infect 2009;10:563-570.
39. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ 1996;312:338-345.
40. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39:650-655.